Product Description
Urapidil 99%min Pharmaceutical API Hypertension drugs made in china 34661-75-1
AI Product Description
*The following content is generated by AI and is for reference only.
Urapidil, a potent antihypertensive agent manufactured in China with high purity standards (typically ≥99%), serves as a critical pharmaceutical active ingredient for managing acute and chronic hypertension. Chemically known as 4-(2-furyl)-1-[3-(2-methoxyphenoxy)propyl]piperazine, its molecular formula is C18H22N2O3. The compound is identified by the CAS number 65730-68-1. Unlike many traditional beta-blockers or calcium channel blockers, Urapidil possesses a unique dual mechanism of action that distinguishes it within cardiovascular therapy. It functions primarily as a selective alpha-1 adrenergic receptor antagonist, which induces vasodilation by relaxing vascular smooth muscle, thereby reducing peripheral resistance. Simultaneously, it acts as an agonist at central serotonin 5-HT1A receptors, modulating sympathetic outflow from the brainstem to lower blood pressure without significantly affecting heart rate. This balanced profile makes it particularly effective for hypertensive emergencies, perioperative hypertension, and severe essential hypertension where rapid yet controlled blood pressure reduction is required.
Manufactured in China using advanced synthesis techniques, Urapidil API meets international quality specifications such as USP and EP standards, ensuring high efficacy and safety for global distribution. Its availability in high-purity forms allows pharmaceutical companies to formulate various dosage forms, including intravenous injections for immediate clinical use and oral tablets for long-term maintenance therapy. The drug is widely recognized for its hemodynamic stability, making it suitable for patients with renal impairment or those requiring precise titration during surgical procedures. Furthermore, its favorable side-effect profile minimizes risks associated with reflex tachycardia or excessive hypotension often seen with other vasodilators. As the demand for reliable antihypertensive solutions grows globally, Chinese-manufactured Urapidil remains a cornerstone in modern cardiovascular pharmacotherapy, offering healthcare providers a versatile tool to manage complex hypertension cases effectively while maintaining rigorous quality control throughout the supply chain.